MSH2 and endometrial cancer: Expression of hMLH1, hMSH2, and EPCAM is suppressed by promoter hypermethylation, which inhibits direct or indirect DNA mismatch repair and contributes to development of endometrial cancer type 1 and development of endometrial cancer in Lynch syndrome.